Back to search results

Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP)

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

Immune Thrombocytopenia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

    Contact: Study coordinator (Heng Mei, Ph.D&M.D.) · hmei@hust.edu.cn

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

    Contact: Study coordinator (Heng Mei) · hmei@hust.edu.cn · 07596503286
    Contact: Study coordinator (Jinhui Shu) · sjh18326016087@163.com · 18326016087
Study leads

  • Heng Mei, Ph.D&M.D

    Principal Investigator

    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

View source on ClinicalTrials.gov(opens in a new tab)